CY1118559T1 - 2,6-DIAMINO-PYRIMIDIN-5-YLO-CARBOXAMIDES AS SUSPENSIONS OF SYK-JAK CHINESE - Google Patents

2,6-DIAMINO-PYRIMIDIN-5-YLO-CARBOXAMIDES AS SUSPENSIONS OF SYK-JAK CHINESE

Info

Publication number
CY1118559T1
CY1118559T1 CY20161101026T CY161101026T CY1118559T1 CY 1118559 T1 CY1118559 T1 CY 1118559T1 CY 20161101026 T CY20161101026 T CY 20161101026T CY 161101026 T CY161101026 T CY 161101026T CY 1118559 T1 CY1118559 T1 CY 1118559T1
Authority
CY
Cyprus
Prior art keywords
jak
methods
syk
syk kinase
ylo
Prior art date
Application number
CY20161101026T
Other languages
Greek (el)
Inventor
Shawn M Bauer
Zhaozhong J Jia
Yonghong Song
Qing Xu
Mukund Mehrotra
Jack W Rose
Wolin Huang
Chandrasekar Venkataramani
Anjali Pandey
Original Assignee
Portola Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/002420 external-priority patent/WO2009145856A1/en
Application filed by Portola Pharmaceuticals, Inc. filed Critical Portola Pharmaceuticals, Inc.
Publication of CY1118559T1 publication Critical patent/CY1118559T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις του τύπου Ι-ΙΙ και τα φαρμακευτικά αποδεκτά ταυτομερή, άλατα, ή τα στερεοϊσομερή αυτών, τα οποία είναι αναστολείς της κινάσης Syk και/ή JAK. Η παρούσα εφεύρεση επίσης αναφέρεται σε ενδιάμεσα που χρησιμοποιούνται στην σύνθεση τέτοιων ενώσεων, την παρασκευή μίας τέτοιας ένωσης, τις φαρμακευτικές συνθέσεις που περιέχουν μία τέτοια ένωση, τις μεθόδους αναστολής της δραστικότητας της κινάσης Syk και/ή JAK, τις μεθόδους αναστολής της συσσωμάτωσης των αιμοπεταλίων, και τις μεθόδους για την πρόληψη ή τη θεραπεία ενός αριθμού παθήσεων που προκαλούνται τουλάχιστον εν μέρει από την δραστικότητα της κινάσης Syk και/ή JAK, όπως η καρδιαγγειακή νόσος, η φλεγμονώδης νόσος, η αυτοάνοση νόσος και η πολλαπλασιαστική διαταραχή κυττάρων, η θρόμβωση, η αλλεργία, το άσθμα, η ρευματοειδής αρθρίτιδα, η λευχαιμία, ή το λέμφωμα μη-Hodgkin.The present invention relates to compounds of formula I-II and their pharmaceutically acceptable tautomers, salts, or stereoisomers thereof, which are inhibitors of Syk kinase and / or JAK. The present invention also relates to intermediates used in the synthesis of such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibiting the activity of Syk kinase and / or JAK, methods of inhibiting platelet aggregation, and methods for preventing or treating a number of diseases that are at least in part caused by the activity of Syk kinase and / or JAK, such as cardiovascular disease, inflammatory disease, autoimmune disease, and p proliferative cell disorder, thrombosis, allergy, asthma, rheumatoid arthritis, leukemia, or non-Hodgkin's lymphoma.

CY20161101026T 2008-04-16 2016-10-13 2,6-DIAMINO-PYRIMIDIN-5-YLO-CARBOXAMIDES AS SUSPENSIONS OF SYK-JAK CHINESE CY1118559T1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US4539908P 2008-04-16 2008-04-16
US4541708P 2008-04-16 2008-04-16
US4540608P 2008-04-16 2008-04-16
US12034408P 2008-12-05 2008-12-05
US12034808P 2008-12-05 2008-12-05
US12034108P 2008-12-05 2008-12-05
PCT/US2009/002420 WO2009145856A1 (en) 2008-04-16 2009-04-16 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors

Publications (1)

Publication Number Publication Date
CY1118559T1 true CY1118559T1 (en) 2017-07-12

Family

ID=43570275

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101026T CY1118559T1 (en) 2008-04-16 2016-10-13 2,6-DIAMINO-PYRIMIDIN-5-YLO-CARBOXAMIDES AS SUSPENSIONS OF SYK-JAK CHINESE

Country Status (18)

Country Link
AU (1) AU2009251863B2 (en)
BR (1) BRPI0910560B8 (en)
CO (1) CO6331433A2 (en)
CY (1) CY1118559T1 (en)
DK (1) DK2321283T3 (en)
ES (1) ES2597441T3 (en)
GT (1) GT201000298A (en)
HK (1) HK1158179A1 (en)
HU (1) HUE031638T2 (en)
IL (3) IL208637A (en)
LT (1) LT2321283T (en)
MX (1) MX353206B (en)
NI (1) NI201000176A (en)
NZ (1) NZ589314A (en)
PL (1) PL2321283T3 (en)
PT (1) PT2321283T (en)
SI (1) SI2321283T1 (en)
ZA (1) ZA201007045B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2013202496B2 (en) * 2008-06-27 2016-08-04 Celgene Car Llc Heteroaryl compounds and uses thereof
EP2603081B1 (en) 2010-08-10 2016-10-05 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
MX2015009952A (en) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Erk inhibitors and uses thereof.
DK3179858T3 (en) 2014-08-13 2019-07-22 Celgene Car Llc Forms and compositions of an ERK inhibitor
CN114196651B (en) * 2021-12-15 2023-06-30 中国林业科学研究院亚热带林业研究所 New application of D6 protein kinase D6PKL2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2308821T3 (en) * 1997-12-15 2008-12-01 Astellas Pharma Inc. NEW DERIVATIVES OF PIRIMIDIN-5-CARBOXAMIDA.
ATE530530T1 (en) * 2002-06-28 2011-11-15 Astellas Pharma Inc DIAMINOPYRIMIDINE CARBONIC ACID AMIDE DERIVATIVE
JP2009544592A (en) * 2006-07-21 2009-12-17 ノバルティス アクチエンゲゼルシャフト 2,4-Di (arylamino) -pyrimidine-5-carboxamide compounds as JAK kinase inhibitors

Also Published As

Publication number Publication date
SI2321283T1 (en) 2017-01-31
AU2009251863B2 (en) 2014-09-25
BRPI0910560B8 (en) 2023-03-21
BRPI0910560B1 (en) 2023-01-24
IL274522A (en) 2020-06-30
LT2321283T (en) 2016-12-12
IL251655B (en) 2020-05-31
MX2010011464A (en) 2014-06-16
IL208637A (en) 2017-04-30
ZA201007045B (en) 2012-08-29
NZ589314A (en) 2012-10-26
CO6331433A2 (en) 2011-10-20
AU2009251863A1 (en) 2009-12-03
AU2009251863A2 (en) 2011-06-09
DK2321283T3 (en) 2016-10-31
PT2321283T (en) 2016-10-19
PL2321283T3 (en) 2017-01-31
IL208637A0 (en) 2010-12-30
BRPI0910560A2 (en) 2021-04-27
ES2597441T3 (en) 2017-01-18
HK1158179A1 (en) 2012-07-13
IL251655A0 (en) 2017-06-29
MX353206B (en) 2018-01-08
GT201000298A (en) 2014-05-07
HUE031638T2 (en) 2017-07-28
NI201000176A (en) 2011-08-08

Similar Documents

Publication Publication Date Title
CY1118559T1 (en) 2,6-DIAMINO-PYRIMIDIN-5-YLO-CARBOXAMIDES AS SUSPENSIONS OF SYK-JAK CHINESE
CY1119771T1 (en) AMINOPYRIMININYLIUM COMPOUNDS AS SUSPENSIONS TOY JAK
CY1126044T1 (en) PYRAZOLO[1,5-ALPHA]PYRIMIDINES USABLE AS ATR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES
CY1125110T1 (en) BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS
MY155639A (en) 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
CY1125613T1 (en) 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4- IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
CY1121433T1 (en) PRODUCTS OF BICYCLE HETEROCYCLES AS INHIBITORS IRAK4
CY1111203T1 (en) 4-ANILINOKINOLINO-3-CARBOXAMIDE AS MOVEMENT INHIBITORS CSF-1R
CY1113324T1 (en) Substituted Amide Derivatives as Protein Kinase Suspensions
CY1119004T1 (en) DIAHYDROPYRIDONE P1 AS AN OPTIONAL CHIA
CY1119678T1 (en) Pyrimidinones as suspensions
CY1122601T1 (en) GSK3 INHIBITORS AND METHODS OF USING THEREOF
CY1122182T1 (en) IMMUNOSUPPRESSANT PHARMACEUTICAL FORMS
EA201891091A1 (en) JAK KINASE INHIBITOR COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASE
EA201890888A1 (en) NEW SPIRO [3H-INDOL-3,2'-PYRROLIDIN] -2 (1H) -ONE COMPOUNDS AND DERIVATIVES AS INHIBITORS MDM2-P53
MX2013012776A (en) Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors.
EA201592199A1 (en) BIPYRAZOL DERIVATIVES AS JAK INHIBITORS
EA201691302A1 (en) NEW HETEROCYCLIC COMPOUNDS
CY1118128T1 (en) Aryl dihydropyridines and piperidinones as MGAT2 inhibitors
EA201991884A2 (en) G12C KRAS INHIBITORS
EA200870117A1 (en) AZAINDOL INHIBITORS AURORA-KINAZ
EA201792116A1 (en) JANUS KINASE INHIBITOR
CY1118093T1 (en) PHARMACEUTICAL FORMS CONTAINING DERIVATIVES 1- (BHTA-D-GLYCOPYRANOZYL) -2-THYNYLMETHYLBENZOLI AS SGLT ANALYPES
CY1116645T1 (en) NOTCH-SUSPENSION SIGNAL PATH
EA201492170A1 (en) NEW CYPRIDE N-PYRIDINYLAMIDES SUBSTITUTED AS A KINAZ INHIBITOR